Navigation Links
Pharmaceutical Pricing and Health Outcomes Top Trending News This Week from HealthEconomics.Com
Date:3/15/2013

Ponte Vedra Beach, FL (PRWEB) March 15, 2013

Top story: The top read story on HealthEconomics.Com was a blog posting on HealthEconomics.Com’s blog, tHEORetically Speaking, by Debra Gordon, MS, entitled “Pricing Cars Like Healthcare”. Medical procedures and therapeutic interventions provided by hospitals have vastly different price points, even for those patients who desire to pay out-of-pocket, and it is exceedingly hard to determine a price at all. Ms. Gordon compares this lack of price transparency within the healthcare sector with the ease of price comparison for common consumer goods, like automobiles or car-related parts. The issues associated with health policy and pricing are debated each week on the tHEORetically Speaking blog.

Another story in HealthEconomics.Com focused on the dilemma among the pharmaceutical industry C-Suite executives who believe that the constantly evolving business model among major payers and managed markets is a “pain point”, according to research by Cegedim discussed in a Medical Marketing & Media Leadership Exchange. The silo approach currently used by pharma to address payer issues results in separation between marketing, sales, and managed markets departments. This results in a lack of understanding, inconsistency of message, market access challenges, and resource waste. This organizational breakdown is also evident in the lack of a focused digital strategy by pharma for the payer audience. HealthEconomics.Com covered this important story, and provides in-depth strategies and tactics to the pharmaceutical indus
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Keryx Biopharmaceuticals to Present at the 25th Annual ROTH Conference
2. Regeneron Pharmaceuticals’ Industrial Operations & Product Supply Site Receives International Recognition for Operational Excellence
3. Leica Biosystems and Synthon Biopharmaceuticals Partner to Develop a Companion Diagnostic Program for Targeted Cancer Therapies
4. ISPE Conference to Benchmark and Advance Quality by Design in the Biopharmaceutical Industry
5. Radiopharmaceuticals Market - Global Industry Analysis, Size, Share, Trends And Forecast, 2012 - 2018: MarketResearchReports.Biz
6. Alexandria Real Estate Equities, Inc. Announces Long-Term Lease with Leading Global Commercial-Stage Oncology Company, Onyx Pharmaceuticals, Inc., for New Build-to-Suit Facility in South San Francisco, California
7. AVANIR Pharmaceuticals To participate in two conferences in March
8. Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2012 Financial Results and Guidance for 2013
9. Serialization in Pharmaceuticals, a Webinar Presented by Xtalks
10. A Look Inside, Factors of Health - Research Report on Novogen Limited, Sanofi SA, ISIS Pharmaceuticals, Inc., Amgen, Inc. and Gilead Sciences, Inc.
11. Patheon Exhibits at the 2013 Biopharmaceutical Development and Production Week
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... NEW YORK , May 29, 2015 /PRNewswire/ ... a specialty pharmaceutical and medical device company focused ... of primary and metastatic liver cancers, announces that ... the treatment of uveal melanoma patients with hepatic ... Delivery System, were highlighted in an on-line abstract ...
(Date:5/29/2015)... 29, 2015  Caris Life Sciences ® , ... promise of precision medicine, today announced the presentation ... clinical utility of Caris Molecular Intelligence ® , ... helping to identify targeted treatment options for patients ... the studies, results of which are to be ...
(Date:5/29/2015)... WISCONSIN (PRWEB) May 29, 2015 Results ... virus talimogene laherparepvec and its ability to reduce the ... treatment have been published in the Journal of Clinical ... patients with stages IIIB, IIIC and IV melanoma, a ... of the study was to evaluate the safety and ...
(Date:5/28/2015)... , May 28, 2015 ... announced the addition of Jain PharmaBiotech,s new ... and Companies"  to their offering.  ... remains a challenge in management. With nearly ... the seven major markets of the world ...
Breaking Biology Technology:Positive Data With Delcath's CHEMOSAT Highlighted At ASCO 2015 2Positive Data With Delcath's CHEMOSAT Highlighted At ASCO 2015 3Positive Data With Delcath's CHEMOSAT Highlighted At ASCO 2015 4Positive Data With Delcath's CHEMOSAT Highlighted At ASCO 2015 5Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 2Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 3Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 4Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 5Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 6Study Published in Journal of Clinical Oncology Reports Talimogene Laherparepvec Improvesdurable Responses in Patients with Advanced Melanoma 2Global Alzheimer Disease Report 2015-2024 - New Drugs, Markets and Companies 2Global Alzheimer Disease Report 2015-2024 - New Drugs, Markets and Companies 3
... ... ... var ... so we need to grab the first one. for (var r in data.results) { first_result = data.results[r]; break; } ...
... 2010 The clinical trials program at UC San ... recognized educational programs of its kind in the world, ... Trials Administration in Latin America Certificate. Classes ... experience. Medica Sur, one of the most respected physician/research ...
... 30, 2010 ... ... ... Results are keyed by longUrl, so we need to grab the first one. for (var r in data.results) { ...
Cached Biology Technology:Biovista Announces a Drug Repositioning Collaboration With Pfizer 2Biovista Announces a Drug Repositioning Collaboration With Pfizer 3Biovista Announces a Drug Repositioning Collaboration With Pfizer 4Biovista Announces a Drug Repositioning Collaboration With Pfizer 5Biovista Announces a Drug Repositioning Collaboration With Pfizer 6Biovista Announces a Drug Repositioning Collaboration With Pfizer 7Biovista Announces a Drug Repositioning Collaboration With Pfizer 8UC San Diego Offers New Certificate for Clinical Trials Administration in Latin America 2ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 2ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 3ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 4ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 5ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 6ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 7ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 8ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 9ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 10ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 11ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 12ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 13ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 14ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 15ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 16ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 17ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 18ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 19ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 20ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 21ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 22ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 23ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 24ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 25ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 26ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 27ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 28
(Date:5/29/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/2w6zgs/facial ... "Facial Recognition Market by Solution, by Software, by ... 2020" report to their offering. ... technology become more efficient and cost effective. This ... investment from the commercial sector. The development of ...
(Date:5/28/2015)... 28, 2015 Industry analyst firm n-tech ... report titled "Markets for Self-Healing Materials: 2015-2022." According to ... and vascular systems, biomaterials, relevant shape memory materials ... $2.7 billion by 2020. The report ... of smart materials. Other recent n-tech reports have included ...
(Date:5/27/2015)... 2015   Codonics (codonics.com), a ... image documentation solutions and Omnicell  (omnicell.com), ... solutions, is pleased to announce their state ... Label System® (SLS), an award-winning FDA class ... Omnicell Anesthesia Workstation, helps prevent medication errors, ...
Breaking Biology News(10 mins):Global advanced Facial Recognition Market Expected to Grow From $2.77 Billion in 2015 to $6.19 Billion in 2020, at an Estimated CAGR of 17.4% 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 3Codonics and Omnicell Expand Partnership 2Codonics and Omnicell Expand Partnership 3Codonics and Omnicell Expand Partnership 4
... in which the circulating strains of influenza showed genetic ... flu shot was found to be effective in preventing ... vaccine also prevented illnesses but was less effective. , ... infection, a University of Michigan study found. , ...
... Muscle weakness and fiber deterioration seen in muscular dystrophy ... under study for their effects against cancer, a Burnham ... on the potential use of these drugs, called histone ... muscles, thereby countering the progression of the disease, in ...
... an innovative new project being developed by Central Queensland ... around the country could soon have access to rehabilitation ... than having to travel to special outpatient clinics. , ... on-line outpatient rehabilitation service for people who have had ...
Cached Biology News:Flu shot effective against drifted influenza, nasal spray vaccine less so 2Flu shot effective against drifted influenza, nasal spray vaccine less so 3Experimental cancer drugs counter muscle deterioration seen in muscular dystrophy 2
...
Request Info...
Streptomycin sulfate an aminoglycoside used for bacterial selection binds to the small ribosomal subunit and interferes with protein biosynthesis.21H39N7O12)2x3H2SO4Formula weight:...
Adducin beta (C-16)...
Biology Products: